Overall survival (OS) results of phase III ARAMIS study of darolutamide (DARO) added to androgen deprivation therapy (ADT) for non-metastatic castration-resistant prostate cancer (nmCRPC)

M. Boegemann, K. Fizazi, N. Shore, T. L. Tammela, A. Ulys, E. Vjaters, S. Polyakov, M. Jievaltas, M. Luz, B. Alekseev, I. Kuss, M. -A. Le Berre, O. Petrenciuc, A. Snapir, T. Sarapohja, M. R. Smith

Research output: Contribution to journalMeeting Abstractpeer-review

Original languageEnglish
Article number149
Pages (from-to)225-225
Number of pages1
JournalOncology Research and Treatment
Issue numberSUPPL 4
Publication statusPublished - Oct 2020
Externally publishedYes
EventAnnual Meeting of the German, Austrian and Swiss Societies for Hematology and Medical Oncology - virtual /Congress Center Basel, Basel, Switzerland
Duration: 9 Oct 202011 Oct 2020

Field of Science*

  • 3.2 Clinical medicine
  • 3.1 Basic medicine

Publication Type*

  • 3.3. Publications in conference proceedings indexed in Web of Science and/or Scopus database

Cite this